Business Context and Reporting Period
Company: Genmab A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2026
Filing Date: May 7, 2026
Principal Executive Offices: Carl Jacobsens Vej 30, 2500 Valby, Denmark
Financial Metrics
The provided filing text serves as a cover sheet and signature page for Form 6-K. It references an "Interim Report Dated May 7, 2026" as Exhibit 99.1 but does not contain the actual financial data within this text.
- Revenue: Not provided in filing text.
- Profit: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific financial figures or operational data to compare against prior periods. Consequently, no material changes in revenue, profit, or other metrics can be identified from this document alone.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. These items are likely contained within the referenced Exhibit 99.1 (Interim Report), which is not included in the input content.
Key Facts for Investor Verification
- Missing Financial Data: The input text is a procedural cover sheet; investors must access Exhibit 99.1 to review the actual interim financial results.
- Reporting Status: Genmab A/S files annual reports under Form 20-F.
- Authorization: The report was signed by Anthony Pagano, Executive Vice President & Chief Financial Officer.
- Reference Incorporation: This report is incorporated by reference into multiple Form S-8 registration statements.